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Summary
Prostaglandins (PGs) are potent stimulators of bone formation and resorption and are produced by bone cells. PGs also have inhibitory
effects on fully differentiated osteoblasts and osteoclasts. This complex, multifunctional regulation is probably mediated by different PG
receptors. Endogenous PGs in bone are produced largely by induction of COX-2, which is highly regulated by hormones and local factors.
The development of specific agonists and antagonists for PG receptors and for COX-2 should allow us to define the physiologic and
pathophysiologic roles of PGs more precisely and develop new therapeutic approaches to metabolic and inflammatory disorders of the
skeleton.
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Prostaglandins (PGs) are potent, multifunctional regulators
of bone metabolism which have both stimulatory and inhibi-
tory effects.1,2 Moreover, skeletal tissue is an abundant
source of PG production, so that endogenous PGs are
likely to play important roles in skeletal physiology and
pathophysiology. Recent studies have suggested that there
are multiple pathways and receptors for PG responses in
skeletal tissues involving different receptors. Other studies
have emphasized the central role of inducible prostaglan-
din G/H synthase or cyclooxygenase (COX-2) in skeletal
metabolism.osteoblastic colony formation.
production by further inducing COX-2.Prostaglandins and bone resorption
Prostaglandins stimulate bone resorption by increasing
the number and activity of osteoclasts. PGE2 is the most
potent agonist, although other prostanoids, particularly
prostacyclin (PGI2) are potent stimulators. PGs appear to
play a critical role in the development of tartrate-resistant
acid phosphatase positive (TRAP+) giant cells with osteo-
clastic features in marrow cell cultures. The ability of a
number of stimulators to increase TRAP+ cells in such
cultures can be blocked by inhibiting endogenous PG
synthesis.3–6 On the other hand, the function of fully-
developed osteoclasts is inhibited by PGs.6 This inhibitory
effect is relatively transient and difficult to elicit in vivo.
Most of the potent stimulators of bone resorption
increased prostaglandin production in bone by induction
of COX-2, although they also stimulate resorption by
PG-independent pathways.1,3,7 Knocking out the COX-2
gene results in marked impairment of osteoclastogenesis
[Y. Okada and C. Pilbeam, unpublished observations].
Both stimulation and inhibition of resorption by PGs can
be mimicked by cyclic AMP analogs. There are two PG
receptors in bone cells which can increase cyclic AMP,
the EP2 and EP4 receptors. The EP4 receptor may be
8important in mediating the stimulation of bone resorption.
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PGs can stimulate bone formation by increasing repli-
cation and differentiation of osteoblasts.9 This effect is
associated with an increase in the production of growth
factors. There is indirect evidence that stimulation of bone
formation is mediated by the EP2 receptor, which is
expressed in osteoblast precursor cells.9,10
Once the osteoblast is fully differentiated, high con-
centrations of PGs can inhibit collagen synthesis. This
inhibitory effect appears to be mediated by a receptor
selective for prostaglandins of the F series, which has been
demonstrated in differentiated osteoblasts.11,12
The role of endogenous prostaglandins in bone
formation probably depends both on the site and cell type
of PG production in the skeleton. The inhibitory effects of
IL-1 on collagen gene transcription in vivo may be mediated
by endogenous PGs.13 In cultures of marrow stromal
cells, dexamethasone can inhibit and PGs can stimulate
14Physiologic role of PGs in bone
Based on their effects and abundant production in
skeletal tissues, it seems highly likely that PGs are import-
ant in regulation of bone turnover. One physiologic role for
PGs may be to mediate the response to mechanical forces.
Stimulation of bone formation by impact loading can be
blocked by NSAIDs.15 An increase in prostaglandin pro-
duction with impact loading has been demonstrated in
humans.16 Fluid shear stress, which would increase during
mechanical loading also can induce COX-2.17 The ability of
small signals from osteocytes to alter bone cell function
may be dependent on the ability of PGs to autoamplify their
18Pathophysiologic roles
The first indication that endogenous prostaglandins
might play a pathophysiologic role was in animal models of
420 L. G. Raisz: Prostaglandins and bonehypercalcemia of malignancy, but this mechanism is rela-
tively uncommon in humans.19 A greater role for en-
dogenous PGs has been postulated for bone loss in
inflammatory disease, including periarticular bone loss in
inflammatory arthritis and alveolar bone loss associated
with periodontitis.20 A role for endogenous PGs in patho-
logic bone formation is supported by studies showing that
heterotopic ossification after orthopedic procedures can be
markedly diminished by NSAID therapy.21
A role for endogenous PGs in the pathogenesis of
osteoporosis is supported by studies in animal models. The
supernatant of the marrow from ovariectomized mice
stimulates bone resorption in calvarial organ cultures by a
prostaglandin-dependent mechanism, involving COX-2
induction.22 Data on osteoporosis in humans are limited.
Long-term use of aspirin is associated with a slightly higher
bone mass, but no difference in fracture rates.23 One
unusual disorder which may be mediated by endogenous
PGs is Caffey’s disease. This disease of periosteal new
bone formation is mimicked in neonates who are given PG
infusions to maintain patency of the ductus arteriosis, and
24can be treated with NSAIDs.Conclusion
The skeleton clearly is a major target organ for PGs.
However, because of the complexity of responses in bone
cells, it is difficult to identify precisely the physiologic and
pathophysiologic roles of PGs. The possible therapeutic
use of new COX-2 selective NSAIDs for bone loss is
certainly worthy of pursuit. The recent evidence that differ-
ent receptors might mediate the stimulation of bone resorp-
tion and of bone formation by prostaglandins should lead to
a search for selective agonists and inhibitors of these
receptors. With current methods of molecular biology and
molecular modeling, it should be possible to identify sites
and pathways for PG production and response in the
skeleton and to manipulate these responses in ways that
will improve the management of skeletal disorders.References
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